— Know what they know.
Not Investment Advice

ENZC OTC

Enzolytics Inc.
1W: -20.0% 1M: -33.3% 3M: -55.6% YTD: +33.3% 1Y: +100.0% 3Y: -99.0% 5Y: -99.7%
$0.00
+0.00 (+0.00%)
 
Weekly Expected Move ±46.8%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 44 · $1.9M mcap · 4.74B float · 0.144% daily turnover · Short 20% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.9M
52W Range0.000199999995-0.0013
Volume24,600
Avg Volume6,820,383
Beta0.51
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSteven Sharabura
Employees1
SectorHealthcare
IndustryBiotechnology
IPO Date2009-04-08
2000 North Central Expressway
Plano, TX 75074
US
972 292 9414
About Enzolytics Inc.

Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms